{"id":"https://openalex.org/W2584301648","doi":"https://doi.org/10.1208/s12248-017-0049-9","title":"Liposomal Drug Product Development and Quality: Current US Experience and Perspective","display_name":"Liposomal Drug Product Development and Quality: Current US Experience and Perspective","alternate_titles":[],"publication_year":2017,"publication_date":"2017-02-03","ids":{"openalex":"https://openalex.org/W2584301648","doi":"https://doi.org/10.1208/s12248-017-0049-9","mag":"2584301648","pmid":"https://pubmed.ncbi.nlm.nih.gov/28160164"},"language":"en","primary_location":{"id":"doi:10.1208/s12248-017-0049-9","doi":"https://doi.org/10.1208/s12248-017-0049-9","is_oa":false,"landing_page_url":"https://doi.org/10.1208/s12248-017-0049-9","pdf_url":null,"source":{"id":"https://openalex.org/S74983066","display_name":"The AAPS Journal","issn_l":"1550-7416","issn":["1550-7416"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2584301648"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000724815","display_name":"Mamta Kapoor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mamta Kapoor","raw_affiliation_strings":["Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024161461","display_name":"Sau L. Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sau L. Lee","raw_affiliation_strings":["Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050870917","display_name":"Katherine M. Tyner","orcid":"https://orcid.org/0000-0003-3812-6381","observed_orcids":["https://orcid.org/0000-0003-3812-6381"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Katherine M. Tyner","raw_affiliation_strings":["Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA. katherine.tyner@fda.hhs.gov","Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA. katherine.tyner@fda.hhs.gov","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]},{"raw_affiliation_string":"Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5050870917"],"corresponding_institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"],"apc_list":{"value":5090,"currency":"USD","value_usd":5090},"apc_paid":null,"fwci":0.6909,"has_fulltext":false,"cited_by_count":130,"citation_normalized_percentile":{"value":0.56112469,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"19","issue":"3","first_page":"632","last_page":"641"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.017500000074505806,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.006599999964237213,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmaceutical-product-development","display_name":"pharmaceutical product development","score":0.7749999761581421},{"id":"https://openalex.org/keywords/drug-quality","display_name":"drug quality","score":0.5109999775886536},{"id":"https://openalex.org/keywords/critical-quality-attributes","display_name":"critical quality attributes","score":0.8880000114440918},{"id":"https://openalex.org/keywords/pharmaceutical-manufacturing","display_name":"pharmaceutical manufacturing","score":0.43299999833106995},{"id":"https://openalex.org/keywords/regulatory-submissions","display_name":"regulatory submissions","score":0.621999979019165},{"id":"https://openalex.org/keywords/investigational-new-drug-application","display_name":"Investigational New Drug application","score":0.8339999914169312},{"id":"https://openalex.org/keywords/new-drug-application","display_name":"new drug applications","score":0.8270000219345093},{"id":"https://openalex.org/keywords/abbreviated-new-drug-application","display_name":"abbreviated new drug application","score":0.906000018119812},{"id":"https://openalex.org/keywords/doxorubicin-hydrochloride","display_name":"doxorubicin hydrochloride","score":0.8730000257492065},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.8050000071525574}],"concepts":[{"id":"https://openalex.org/C185154212","wikidata":"https://www.wikidata.org/wiki/Q410454","display_name":"Liposome","level":2,"score":0.8526831865310669},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.7279168963432312},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5606614351272583},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.5442292094230652},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5307859182357788},{"id":"https://openalex.org/C2779820397","wikidata":"https://www.wikidata.org/wiki/Q1392806","display_name":"Drug delivery","level":2,"score":0.5147133469581604},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.23506087064743042},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.09045681357383728}],"mesh":[{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011786","descriptor_name":"Quality Control","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1208/s12248-017-0049-9","doi":"https://doi.org/10.1208/s12248-017-0049-9","is_oa":false,"landing_page_url":"https://doi.org/10.1208/s12248-017-0049-9","pdf_url":null,"source":{"id":"https://openalex.org/S74983066","display_name":"The AAPS Journal","issn_l":"1550-7416","issn":["1550-7416"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS Journal","raw_type":"journal-article"},{"id":"pmid:28160164","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28160164","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS journal","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W324781303","https://openalex.org/W1248801782","https://openalex.org/W1491628483","https://openalex.org/W1966591029","https://openalex.org/W1973183062","https://openalex.org/W1974913887","https://openalex.org/W1975341277","https://openalex.org/W1989230986","https://openalex.org/W1996044226","https://openalex.org/W1997320844","https://openalex.org/W2007656210","https://openalex.org/W2013089475","https://openalex.org/W2021202523","https://openalex.org/W2022996046","https://openalex.org/W2033222077","https://openalex.org/W2040329251","https://openalex.org/W2050271125","https://openalex.org/W2069444430","https://openalex.org/W2070808114","https://openalex.org/W2075771522","https://openalex.org/W2080993426","https://openalex.org/W2086919915","https://openalex.org/W2091920826","https://openalex.org/W2097603366","https://openalex.org/W2123227439","https://openalex.org/W2123478701","https://openalex.org/W2145186138","https://openalex.org/W2158221216","https://openalex.org/W2171361466","https://openalex.org/W2488382180","https://openalex.org/W2497873100","https://openalex.org/W2555048663"],"related_works":["https://openalex.org/W3183269458","https://openalex.org/W4212801432","https://openalex.org/W4411287552","https://openalex.org/W4405381171","https://openalex.org/W2504578155","https://openalex.org/W7108079595","https://openalex.org/W4412438228","https://openalex.org/W4290045017","https://openalex.org/W2499538566","https://openalex.org/W6930809665"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2584301648","counts_by_year":[{"year":2026,"cited_by_count":11},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":20},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":14},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":5}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2017-02-10T00:00:00"}
